Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TCRX

TCRX - TScan Therapeutics, Inc. Stock Price, Fair Value and News

$1.07-0.05 (-4.46%)
Market Closed

53/100

TCRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

53/100

TCRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.22

Target 3M

$1.16

Target 6M

$1.18

TCRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TCRX Price Action

Last 7 days

-6.1%

Last 30 days

3.9%

Last 90 days

-42.5%

Trailing 12 Months

-56.8%

TCRX RSI Chart

TCRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TCRX Valuation

Market Cap

138.8M

Price/Earnings (Trailing)

-0.97

Price/Sales (Trailing)

15.83

Price/Free Cashflow

-1.02

TCRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.22

Target 3M

$1.16

Target 6M

$1.18

TCRX Fundamentals

TCRX Revenue

Revenue (TTM)

8.4M

Rev. Growth (Yr)

-44.73%

Rev. Growth (Qtr)

-14.6%

TCRX Earnings

Earnings (TTM)

-142.6M

Earnings Growth (Yr)

-19.48%

Earnings Growth (Qtr)

3.36%

TCRX Profitability

Return on Equity

-99.01%

Return on Assets

-54.38%

Free Cashflow Yield

-97.85%

TCRX Investor Care

Shares Dilution (1Y)

19.00%

Diluted EPS (TTM)

-1.11

TCRX Alerts

  • 1 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
202416.4M16.7M16.5M2.8M
202317.3M16.4M16.9M21.0M
202211.1M12.3M13.3M13.5M
20213.3M5.6M7.9M10.1M
20200001.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About TScan Therapeutics, Inc.

TCRX
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors. In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEtscan.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES135

TScan Therapeutics, Inc. Frequently Asked Questions

TCRX is the stock ticker symbol of TScan Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of TScan Therapeutics, Inc. is 138.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check TCRX's fair value in chart for subscribers.

The fair value guage provides a quick view whether TCRX is over valued or under valued. Whether TScan Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact TScan Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TCRX.

As of Wed Jan 28 2026, TCRX's PE ratio (Price to Earnings) is -0.97 and Price to Sales (PS) ratio is 15.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TCRX PE ratio will change depending on the future growth rate expectations of investors.